Lack of tocilizumab effect on mortality in COVID19 patients

Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2020-10, Vol.10 (1), p.17100-17100, Article 17100
Hauptverfasser:	Holt, Gregory E., Batra, Mayank, Murthi, Mukunthan, Kambali, Shweta, Santos, Kayo, Bastidas, Maria Virginia Perez, Asif, Huda, Haddadi, Sara, Arias, Sixto, Mirsaeidi, Mehdi
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/409 692/699 Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - immunology Antibodies, Monoclonal, Humanized - therapeutic use Betacoronavirus - isolation & purification Coronavirus Infections - drug therapy Coronavirus Infections - mortality Coronavirus Infections - virology COVID-19 Female Ferritins - analysis Humanities and Social Sciences Humans Interleukin-6 - analysis Male Middle Aged multidisciplinary Odds Ratio Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - mortality Pneumonia, Viral - virology Proportional Hazards Models Receptors, Interleukin-6 - immunology SARS-CoV-2 Science Science (multidisciplinary) Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t imply causality however lack of improvement by tocilizumab requires further clinical trial alterations.
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-020-74328-x